Probe • Vol LXII • No. 4 • Sep–Dec 2023 • 5 Efficacy and Safety of Diabecon in the Management of Non–Insulin-Dependent Diabetes Mellitus and burning sensation (hands and soles) in both the groups. No clinically significant changes were observed in the hematological and biochemical parameters. No adverse reactions were reported, and the overall compliance to the treatment was excellent. Discussion The synergistic action of the ingredients of Diabecon shows beneficial effects in NIDDM. Gymnemic acids, active ingredients of Gymnema sylvestre, help correct the metabolic derangements in the diabetic liver, kidney, and muscle and reverse the pathological changes that occur during the hyperglycemic phase. Epicatechin, an active ingredient of Pterocarpus marsupium, possesses antihyperglycemic activity and also renormalizes the activities of hexokinase, glucokinase, and phosphofructokinase. Eugenia jambolana significantly reduces blood glucose, blood urea, and cholesterol levels. Boerhaavia diffusa significantly reduces glycosylated hemoglobin and increases the level of total hemoglobin. Tribulus terrestris inhibits gluconeogenesis and significantly reduces plasma triglyceride levels. Ocimum sanctum significantly lowers FBSL, uronic acid, total amino acid, total cholesterol, triglyceride, phospholipid, and total lipid levels. O sanctum renormalizes the glycogen concentration in various tissues. Conclusion Diabecon is safe and clinically effective as a monotherapy in patients with newly diagnosed NIDDM and as an adjuvant for patients using conventional OHAs. Summary • Fifty patients with non–insulin-dependent diabetes mellitus (NIDDM) were included in this study: 25 patients (group 1) had recently diagnosed NIDDM and were not consuming any oral hypoglycemic agent (OHA), and 25 patients (group 2) had NIDDM and were consuming OHAs. • All patients were advised 2 tablets of Diabecon, BID, for 3 months. • Both the groups showed a significant improvement in symptoms of NIDDM such as polyuria, generalized weakness, and loss of appetite. • The overall compliance to the treatment was excellent, with no adverse reactions. Figure 1. Reduction in Blood Sugar Level in Patients With Recently Diagnosed NIDDM and After Treatment With Diabecon Alone NIDDM, non–insulin-dependent diabetes mellitus. Figure 2. Reduction in Blood Sugar Level in Patients With NIDDM Consuming Conventional OHAs and Diabecon NIDDM, non–insulin-dependent diabetes mellitus; OHAs, oral hypoglycemic agents. 300 250 100 50 150 200 Fasting Postprandial 0 Blood Sugar, mg% Baseline Month 1 Month 2 Month 3 300 250 100 50 150 200 Fasting Postprandial 0 Blood Sugar, mg% Baseline Month 1 Month 2 Month 3
RkJQdWJsaXNoZXIy MjAwNDg=